Troriluzole failed a phase 3 trial in spinocerebellar ataxia in 2022. Based on talks with the FDA, Biohaven kept tracking ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

Courtney Walker, Chief Growth Officer at MMC and RXMosaic, discusses the evolving role of communicators and the future of the healthcare industry. AI will significantly transform the field, ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...